

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A01H 5/00, 5/10, C12N 5/14, 15/31, 15/52, 15/82</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/49888</b> (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: <b>PCT/US98/09013</b> (22) International Filing Date: <b>6 May 1998 (06.05.98)</b> (30) Priority Data: <b>60/045,725</b> <b>6 May 1997 (06.05.97)</b> <b>US</b> (71) Applicant: <b>KANSAS STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; 1500 Hayes Drive, Manhattan, KS 66502-5068 (US).</b> (72) Inventor: <b>LI, Yi; 1721 King's Road, Manhattan, KS 66503 (US).</b> (74) Agents: <b>FERBER, Donna, M. et al.; Greenlee, Winner and Sullivan, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO 80303 (US).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i>	
(54) Title: <b>TRANSGENIC SEEDLESS FRUIT AND METHODS</b>  (57) Abstract  <p>The present invention provides methods and DNA constructs for the genetic engineering of plant cells to produce plants which produce substantially seedless fruit in the absence of exogenous growth factors (auxins or cytokinins) and in the absence of pollination. The substantially seedless fruits produced by the methods described herein are about the size of wildtype seeded fruit (or somewhat larger) and these fruits are equal to or superior to the wildtype seeded fruit with respect to solid content and flavor. The seedless fruits of the present invention are produced in transgenic plants which contain and express auxin or cytokinin biosynthetic genes, e.g., tryptophan oxygenase or isopentenyl transferase coding sequences expressed under the regulatory control of sequences directing preferential or tissue specific expression of a downstream gene in the ovaries or developing fruit.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	IS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## TRANSGENIC SEEDLESS FRUIT AND METHODS

## CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from United States Provisional Application No. 60/045,725, filed May 6, 1997.

## 5 ACKNOWLEDGEMENT OF FEDERAL RESEARCH SUPPORT

This invention was made, at least in part, with funding from the United States Department of Agriculture and the National Aeronautics and Space Administration. Accordingly, the United States Government may have certain rights in this invention.

## THE BACKGROUND OF THE INVENTION

10 The invention relates generally to genetic engineering and, more particularly, to a means and method for making plants which produce substantially seedless fruit, wherein the seedless fruit has desirable taste and size characteristics, rendering it more appealing than naturally occurring fruit to the consumer.

15 Parthenocarp, the production of seedless fruits, can be achieved by the addition of the plant growth regulators auxin, cytokinin or gibberellin in many crop species (see, e.g., Naylor (1984) in Hormonal Regulation of Development II: the functions of hormones from the levels of the cell to the whole plant, Scott, T., ed., pp. 172-218, Springer-Verlag).

Applications of these hormones to the unfertilized flowers of tomato, pepper, tobacco, holly, fig, cucumber, watermelon, avocado, eggplant, pear, blackberry and many other species,  
20 induced fruit set in the absence of pollen.

It has been shown that the exogenous application of auxin or gibberellin to unfertilized flowers in a number of plant species, including tomato (*Lysopersicon esculentum*) induces fruit set in the absence of pollination, resulting in the production of parthenocarpic fruit [Wareing and Phillips (1981) *Growth and Differentiation in Plants*, Pergamon Press,  
25 Oxford, UK]. By contrast, the exogenous application of cytokinin to ovaries or developing

fruits is less effective for the production of seedless fruits. It is believed that exogenously applied cytokinin cannot reach the site of action for fruit development because the hormone is immobile within the plant.

In previous efforts to produce seedless fruits, traditional plant breeding and exogenous application of hormones have been used with some success. However, the exogenous application of plant hormones is a labor-intensive process, and traditional plant breeding is a long term process. Moreover, at least some of the previous attempts to produce certain seedless fruits have resulted in low numbers of seedless fruits and/or in relatively small seedless fruits as compared with the normal, seeded fruits.

There is a long felt need in the art for an effective and economical means and methods for the production of seedless fruit, particularly in good yield and quality as compared with prior art seedless fruits.

#### SUMMARY OF THE INVENTION

It is an object of the present invention to provide compositions and methods for the production of seedless fruit by transgenic means. This is accomplished by the stable introduction into the plant genome of an expression cassette in which a gene encoding an enzyme involved in the biosynthetic pathway of a plant developmental regulator (cytokinin, auxin or gibberellic acid) is operably linked to transcription control sequences which mediate expression of the linked gene in the proper plant part at the appropriate time during development. As specifically exemplified herein, the gene encodes tryptophan oxygenase (*iaaM* gene) or isopentenyl transferase (*ipt* gene), and the transcriptional regulatory sequences are those from the GH3 gene, directing tissue-specific expression of a downstream coding sequence in the ovary and developing fruit. The nucleotide sequence of a specifically exemplified GH3 regulatory region from *Glycine max* is given in SEQ ID NO:1. Other regulatory sequences which mediate selective expression in the ovary and/or developing fruit can be substituted for the GH3 regulatory and promoter sequences, such as the AGL5 or PLE 36 transcriptional control sequences.

Also provided by the present invention is an expression cassette can be expressed in plant tissue after the introduction of the cassette into plant tissue. A preferred coding sequence of interest is that for an auxin biosynthetic enzyme, a gibberellin biosynthetic gene

or a cytokinin biosynthetic enzyme. The specifically exemplified coding sequence and deduced amino acid sequence for the auxin biosynthetic enzyme (tryptophan oxygenase), are given in SEQ ID NOs:2 and 3, respectively. The specifically exemplified coding sequence and deduced amino acid sequences of the cytokinin biosynthetic enzyme (isopentenyl transferase) are given in SEQ ID NO:4 and 5, respectively. Transcription is regulated by an ovary and developing fruit specific and auxin-inducible transcriptional regulatory sequence (GH3, from *Glycine max*), as specifically exemplified herein. The AGL5 promoter (See SEQ ID NO:7) (from *Arabidopsis thaliana*) operably linked to an *iaaM* or *ipt* coding sequence, also functions in the present invention. It is understood that other tissue-specific regulatory sequences which direct expression of an operably linked coding sequence in the developing ovary or developing fruit can be substituted for the GH3 sequence disclosed herein.

A further aspect of the present invention are transgenic plant cells, plant tissue and plants which have been genetically engineered to contain and express a nucleotide sequence encoding a cytokinin or auxin biosynthetic enzyme under the regulatory control of the tissue-specific transcription regulatory element, such that elevated gibberellin(s), auxin or cytokinin (as compared with normal plant tissue) are produced in the developing ovary or developing fruit such that the fruit so produced is substantially seedless and is increased in solids content as compared with wildtype fruit. Preferably the tissue-specific transcription regulatory element is associated with the GH3 promoter and promoter-associated sequences (e.g., having the specifically exemplified nucleotide sequence given in SEQ ID NO:1) or the tissue-specific promoter is an AGL promoter (active in the ovaries of flowers), as exemplified by the sequence in SEQ ID NO:7.

The present invention provides a method for the production of substantially seedless fruit, said method comprising the steps of constructing an expression cassette in which a coding sequence for an auxin biosynthetic enzyme, cytokinin biosynthetic enzyme, or gibberellin biosynthetic enzyme(s) is operably linked to a transcriptional regulatory sequence which transcription regulatory sequence mediates the expression of a downstream coding sequence in a developing ovary and/or fruit, stably incorporating the expression cassette into a plant cell to produce a stably transformed plant cell and regenerating a transgenic plant from the stably transformed plant cell, whereby substantially seedless fruit having a higher solids content than wildtype fruit are produced when the transgenic plant is cultivated. The auxin

biosynthetic coding sequence can be a tryptophan oxygenase coding sequence, for example, with an amino acid sequence as given in SEQ ID NO:3. The cytokinin biosynthetic coding sequence can be an isopentenyl transferase coding sequence, for example, having an amino acid sequence as given in SEQ ID NO:5.

5           The transcriptional regulatory sequence mediates tissue-specific expression of an operably linked downstream coding sequence in ovary and developing fruit tissue; the regulatory sequence can be an auxin-inducible transcriptional regulatory sequence, for example, the GH3 transcription regulatory sequences given in SEQ ID NO:1, the AGL5 transcriptional regulatory sequences as given in SEQ ID NO:7, 2A11, pTPRPF1, PLE36 or  
10       PZ130 transcription regulatory sequences.

          The present invention further provides a transgenic plant which has been genetically engineered to contain and express an auxin biosynthetic enzyme coding sequence, a cytokinin biosynthetic enzyme coding sequence or gibberellin biosynthetic enzyme's coding sequence under the regulatory control of a tissue-specific transcription regulatory sequence which is  
15       selectively expressing in developing ovary tissue or developing fruit tissue. Seeds and embryos containing the genetically engineered DNA construct are within the intended definition of "plant," as are progeny containing the DNA construct. The auxin biosynthetic coding sequence can be a tryptophan oxygenase coding sequence, or the cytokinin biosynthetic coding sequence can be an isopentenyl transferase coding sequence. Transgenic  
20       plants described herein comprise a transcriptional regulatory sequence which mediates tissue-specific expression of an operably linked downstream coding sequence. The tissue specific regulatory sequence can be an auxin-inducible transcriptional regulatory sequence including, but not limited to, the GH3 sequences as given in SEQ ID NO:1. The transgenic plant producing substantially seedless fruit (e.g., in the absence of pollination) can be a  
25       dicotyledonous plant or a monocotyledonous plant. Such a dicotyledonous plant can be a member of the Solanaceae, including but not limited to, *Lycopersicon esculentum*, or it can be cucumber, watermelon, tobacco, apple, citrus, pear, fig, currant, muskmelon, squash, cherry, sweet potato, grapes, sugar beet, tea, strawberry, blackberry, blueberry, raspberry, loganberry, rose, chrysanthemum, sweet pepper, eggplant, among others. Substantially seedless cotton  
30       can also be produced according to the present invention.

Also provided by the present invention is an expression cassette comprising a coding sequence for an auxin, cytokinin or gibberellin biosynthetic enzyme and a transcription regulatory sequence operably linked thereto, which transcription regulatory sequence mediates the preferential expression of the downstream coding sequence in ovary or developing fruit. The auxin biosynthetic enzyme can be tryptophan oxygenase (also called tryptophan dioxygenase) and the cytokinin biosynthetic enzyme can be isopentenyl transferase. The transcriptional regulatory sequence can be any transcriptional regulatory sequence which specifically mediates gene expression in ovary and/or developing fruit.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photograph of representative wildtype seeded, seedless GH3-*iaaM* and seedless GH3-*ipt* fruits, each of which has been longitudinally sectioned for the photograph.

Figure 2 is a photograph of representative wildtype seedless, seedless GH3-*iaaM* and seedless GH3-*ipt* fruits, each of which has halved along the longitudinal axis.

Figure 3 illustrates a partial restriction map of the GH3-*iaaM*-NOS fusion gene cloned in pUC18.

Figure 4 is a diagram of the GH3-*iaaM*-NOS fusion gene as cloned into pBIN19.

Figure 5 illustrates relevant restriction endonuclease sites used in the construction of the GH3-*ipt*-NOS fusion gene in pUC18.

Figure 6 is a diagram of the GH3-*ipt*-NOS fusion gene as inserted in pBIN19.

Figure 7 is a diagram of the AGL5-*iaaM*-NOS fusion gene as inserted in pBIN19.

Figure 8 is a diagram of the AGL5-*ipt*-NOS fusion gene as inserted in pBIN19.

### DETAILED DESCRIPTION OF THE INVENTION

The following definitions are given in order to provide clarity as to the intent or scope of their usage in the specification and claims.

A non-naturally occurring recombinant nucleic acid molecule, e.g., a recombinant DNA molecule, is one which does not occur in nature; i.e., it is produced either by natural processes using methods known to the art, but is directed by man to produce a desired result or it has been artificially produced from parts derived from heterologous sources, i.e., a DNA construct, which parts may be naturally occurring or chemically synthesized molecules or

portions thereof, and wherein those parts have been joined by ligation or other means known to the art.

A transgenic plant is one which has been genetically modified to contain and express heterologous DNA sequences, either as regulatory RNA molecules or as proteins. As specifically exemplified herein, a transgenic plant is genetically modified to contain and express a heterologous DNA sequence operably linked to and under the regulatory control of transcriptional control sequences by which it is not normally regulated, i.e., under the regulatory control of the tissue-specific transcriptional control sequences of the GH3 gene, for example, of *Glycine max* or of the AGL5 or PLE36 genes. Other tissue-specific regulatory sequences which mediate expression of an operably linked coding sequence in the developing ovary and in developing fruit can be used in place of the GH3 regulatory sequence. The present invention provides for the expression of a nucleotide sequence encoding an auxin biosynthetic enzyme or a cytokinin biosynthetic enzyme expressed under the regulatory control of transcription regulatory sequences expressed in the developing ovary and/or developing fruit of a plant. As specifically exemplified, the regulatory sequences are those of the GH3 gene of *Glycine max*. As used herein, a transgenic plant also refers to those progeny of the initial transgenic plant which carry and are capable of expressing the heterologous coding sequence under the regulatory control of the qualitative and/or quantitative transcription control sequences described herein. Seeds containing transgenic embryos are encompassed within this definition. In the context of the present application, it is understood that the expression cassette is stably maintained in the genome of a transformed host plant cell, plant tissue and/or plant. Because seed formation occurs when flowers of a transgenic plant of the present invention are pollinated, the ordinarily skilled artisan can readily reproduce the plants of the invention.

The term transgenic plant, as used herein, refers to a plant which has been genetically modified to contain and express heterologous DNA. As specifically exemplified herein, a transgenic plant is genetically modified to stably contain and consistently express (at the appropriate time) a seedless phenotype that is not normally present in the plant. As further used herein, a transgenic plant also refers to progeny of the initial transgenic plant, which progeny carry and are capable of expressing the seedless phenotype. Seeds containing transgenic embryo are encompassed within this definition. As used herein, a transgenic plant

is a monocotyledonous or a dicotyledonous plant. Transgenic plants of the present invention can include, without limitation, tobacco, tomato, cucumber, cotton, grapes, tea, strawberry, rose, sweet pepper, hot pepper, eggplant, apple, citrus, pear, fig, currant, squash, watermelon, musk melon, sweet potato, blackberry, blueberry, raspberry, loganberry, other berries, chrysanthemum, among others. Transgenic plant cells and transgenic plant tissue are similarly genetically modified to stably contain heterologous DNA. Transgenic seeds and transgenic embryos are those which contain a specifically regulated DNA construct of the present invention.

A fruit, as used herein, is the structure which surrounds an ovule(s) of a plant. The methods and expression cassettes of the present invention are suited for producing substantially seedless fruits in the tomato, pepper, eggplant, cotton, cucumber, watermelon, raspberry, strawberry, blackberry, apple, citrus, pear, fig, currant, muskmelon, squash, cherry, among others.

A seedless fruit, as used herein, is one which is substantially seedless. Substantially seedless means that there are from 0% to less than about 5% of the normal number of seeds produced per flower, under conditions which are not dependent on pollination. As specifically applied to tomatoes, (substantially) seedless fruits are those with 5 or fewer seeds per fruit. The seedless fruits of the present invention, surprisingly, exhibit an increased solids content as compared with wildtype fruit.

*ipt* is the mnemonic for the isopentenyl transferase gene, which functions in the biosynthesis of the cytokinin isopentenyladenosine. Plants genetically engineered to contain and express a heterologous *ipt* gene contained cytokinin levels about ten-fold greater than normal [Li et al. (1992) 153:386-395; Li et al. (1994) *Plant Science* 100:9-14]. As specifically exemplified herein, *ipt* is from *Agrobacterium tumefaciens*; the nucleotide and deduced amino acid sequences are given in SEQ ID NOs: 4 and 5, respectively.

*iaaM* is the mnemonic for the tryptophan oxygenase gene, which is in the biosynthetic pathway for the biosynthesis of the auxin indoleacetic acid. As specifically exemplified, the *iaaM* gene is from *Agrobacterium tumefaciens* for nucleotide and amino acid sequences, see SEQ ID Nos: 2 and 3.

While the present application specifically exemplifies *iaaM* and *ipt* from *A. tumefaciens*, it is understood by one of ordinary skill in the art that the exemplified *iaaM* can

be replaced by any other plant or bacterial gene whose expression results in elevated auxin (IAA) levels. Suitable replacements include, but are not limited to, *iaaH* (from *A. tumefaciens* or *iaaH* or *iaaM* a plant pathogenic pseudomonad) to elevate auxin production. When operably linked to an appropriate tissue specific transcription regulator/promoter.

5 Suitable replacements for the exemplified *ipt* sequences for increasing cytokinin levels are also within the skill in the art. It is readily understood in the art what procedural modifications are necessary when such substitutions are made. Similarly, any transcription regulatory sequences can replace GH3, provided that an operably linked downstream coding sequence is preferentially or exclusively expressed in the ovary and/or developing fruit.

10 Alternative suitable transcription regulatory sequences include those from genes including, but not limited to, AGL (AGL5 of *Arabidopsis thaliana*) [Savidge et al. 1995 *Plant Cell* 7:721-733], 2A11 [Pear et al. (1989) *Plant Molec. Biol.* 13:639-651], pTPRPF1 from tomato [Salts et al. (1991) *Plant Molec. Biol.* 17:149-150] and the ovary-specific transcription regulatory sequences from PLE36 from tobacco. The tobacco PLE36 gene is identified by the  
15 partial sequence as given in SEQ ID NO:6. The ovary-specific transcription regulatory sequence (in pZ130) from tomato is described in United States Patent No. 5,175,095. Several gibberellin biosynthetic genes [Chiang, et al., (1995) *Plant Cell* 7:195-201; Sun and Kamiya, (1994) *Plant Cell* 6:119-1518; Xu, et al., (1995) *Proc. Natl. Acad. Sci. USA* 92:6640-6644]; or genes involved in gibberellin response [Jacobsen et al. (1996), *Proc. Natl. Acad. Sci. USA*.  
20 93:9292-9296] in flowers and developing fruits are known. Regulated expression of these genes in ovary and/or developing fruit (using tissue specific transcription regulatory sequences as described herein) allows the development of substantially seedless fruit or substantially seedless cotton.

25 Production of seedless cotton fruits in transgenic cotton according to the methods of the present invention improves fiber productivity.

The present invention allows the production of seedless fruits without the expense of application of giberellin(s), auxin or cytokinin to unfertilized flowers or developing fruit, obviating the need for chemicals in the production setting. An added advantage of the present method is that it circumvents the need for pollination for fruit set, thus improving the  
30 efficiency of fruit production. It has been recognized that poor pollination is a major cause of incomplete fruit set and undersized fruit in the greenhouse and in field production of

tomatoes, for example. In addition, the present transgenic methods circumvent any problems associated with uptake of an gibberellin(s), exogenous auxin or cytokinin and transport from a surface to which the exogenous growth regulator has been applied to the developing ovary or fruit.

The present inventor has produced transgenic tomato plants which produce elevated levels of plant hormones such as auxin (e.g., via a GH3 promoter driving expression of an tryptophan oxygenase coding sequence, GH3-*iaaM*) and cytokinin (e.g., via GH3-regulated expression of an isopentenyl transferase coding sequence, GH3-*ipt*) in ovary and developing fruits. The seedless fruits produced by these transgenic tomato plants produced seedless fruits which are significantly larger than wildtype seedless fruits and which, surprisingly, were significantly higher in solids content than wildtype fruits. With normal pollination tomato fruits from the transgenic plants express the GH3-*ipt* construct also show an increase in size when compared to wildtype seeded fruits.

Table 1

Comparison of Seedless and Wildtype Tomatoes

Plant	Average Fruit Weight (% of their wildtype seeded fruits)*
<b>Seedless fruits</b> (less than 5 seeds per fruit)	
wildtype	
GH3- <i>iaaM</i> (auxin overproduction)	23% $\pm$ 16%
GH3- <i>ipt</i> (cytokinin overproduction)	108% $\pm$ 18%
	117% $\pm$ 25%
<b>Seeded fruits</b>	
wildtype	
GH3- <i>iaaM</i> (auxin overproduction)	100% $\pm$ 17%
GH3- <i>ipt</i> (cytokinin overproduction)	138% $\pm$ 18%
	144% $\pm$ 21%

\* Thirty to sixty tomato fruits produced from 5 to 10 plants were analyzed for each group.

When grown in the greenhouse environment, T2 transgenic plants expressing either the GH3-*iaaM* or the GH3-*ipt* expression cassettes are morphologically indistinguishable from wildtype plants. However, the transgenic fruits are significantly larger than the wildtype

fruits. Representative wildtype seeded, seedless GH3-iaaM and seedless GH3-ipt fruits are shown in Figures 1 and 2.

In contrast to unpollinated wildtype fruits, the transgenic fruits of the present invention can grow and develop into normal sized or larger fruits. Studies of these tomatoes have shown that the ripe transgenic tomatoes of the present invention have increased solid content than wildtype fruits, and the taste of the transgenic fruits is not different from the taste of the wildtype fruit. In addition, fruit production according to the present invention is not dependent on pollination, which, in a greenhouse setting, may be poor and/or dependent on mechanical pollination.

By weighing tomatoes before and after freeze-drying, the solids contents of the GH3 promoter-iaaM seedless tomato fruits and the corresponding wildtype seeded fruits were determined. The seedless fruits produced from the GH3 promoter-iaaM tomato plants contain 50-110% more solids (dry matter) than the wildtype seeded fruits (see Table 2). Because yield and quality of tomato fruits and their products depend on contents of solids and the composition of the raw materials in fruits, the seedless tomatoes of the present invention are highly desirable for the tomato processing industry.

Table 2  
Solids Contents of Tomato Fruits

Fruit type	Solids contents
money maker wildtype seeded fruits -- (25 fruits determined):	100%*
money maker GH3 promoter-iaaM seedless fruits -- Fruits from Transgenic Plant 1 (5 fruits determined): -- Fruits from Transgenic Plant 2 (9 fruits determined): -- Fruits from Transgenic Plant 3 (7 fruits determined): -- Fruits from Transgenic Plant 3 (3 fruits determined):	178% 212% 183% 203%
money maker GH3 promoter-ipt seedless fruits -- Fruits from Transgenic Plant 1 (6 fruits determined): -- Fruits from Transgenic Plant 2 (4 fruits determined): -- Fruits from Transgenic Plant 3 (8 fruits determined):	158% 173% 191%

\* Because we compared solids contents of the GH3 promoter-iaaM or GH3 promoter-ipt seedless fruits to those of the wildtype seeded fruits, the solids contents of the wildtype seeded fruits were designated as 100%.

Promoters which are known or are found to cause transcription in plant cells can be used in the present invention. As described below, it is preferred that the particular promoter selected should be selectively expressed in developing fruit or ovary and capable of causing sufficient expression of a cytokinin biosynthetic gene or an auxin biosynthetic gene or a gibberellin biosynthetic gene to result in the production of a substantially seedless fruit in the absence of pollination. This is because an effective amount of auxin, gibberellin, or cytokinin in the ovary or developing fruit can stimulate fruit growth and development without formation of seeds. Seeds are source of endogenous auxin and cytokinin in developing fruits. The amount of auxin, cytokinin, and gibberellin(s) needed to induce fruit growth development in the absence of pollination may vary with the type of plant, and appropriate modulation of the expression of the corresponding gene is well within skill in the art.

The promoters used in the DNA constructs of the present invention may be modified, if desired, to affect their control characteristics. For purposes of this invention, the phrase "promoter" thus includes variations of the promoter, e.g., promoters derived by means of ligation with operator regions, random or controlled mutagenesis as well as tandem of multiple copies of enhancer elements, etc.

The use of an organ-specific promoter is contemplated by the invention. Preferably, the expression of a downstream coding sequence occurs in a tissue specific and developmental stage specific manner. It is preferred that the promoter driving the expression of the gibberellin, auxin or cytokinin biosynthetic gene is selectively expressed in the desired tissue and at the stage of development effective for inducing fruit growth and development.

A coding sequence used in a DNA construct of this invention may be modified, if desired, to create mutants, either by random or controlled mutagenesis, using methods known to those skilled in the art. Those mutants can include synonymous coding sequences which have been modified to optimize the level of expression in a particular host cell, to create or remove restriction endonuclease recognition sites or to otherwise facilitate or accommodate molecular biological manipulations according to the knowledge of one of ordinary skill in the art. Such mutants and variants are therefore within the scope of the present invention.

The 3' non-translated region contains a polyadenylation signal which functions to cause the addition of polyadenylate nucleotides to the 3' end of the RNA. Examples of suitable 3' regions are (1) the 3' transcribed, non-translated regions containing the

polyadenylation signal of the tumor-inducing (Ti) plasmid genes of *Agrobacterium*, such as the nopaline synthase (NOS) gene, and (2) plant genes like the 7S soybean storage protein genes and the pea E9 small subunit of the RuBP carboxylase gene.

The mRNA produced by a DNA construct of the present invention also contains a 5' non-translated leader sequence. This sequence can be derived from the promoter selected to express the gene, and can be specifically modified so as to increase translation of the mRNA. The 5' non-translated regions can be obtained from viral RNAs, from suitable eukaryotic genes, or may be synthesized. The present invention is not limited to constructs, as presented in the following examples, wherein the non-translated region is derived from the 5' non-translated sequence that accompanies the promoter sequence. Rather, the non-translated leader sequence can be part of the 5' end of the non-translated region of the native coding sequence for the dsRNA-binding protein, or part of the promoter sequence, or can be derived from an unrelated promoter or coding sequence as discussed above.

While in most cases the heterologous DNA which is inserted into plant cells contains a gene which encodes a selectable marker such as an antibiotic resistance marker (e.g., the kanamycin/neomycin resistance determinant), this is not mandatory.

A DNA construct of the present invention can be inserted into the genome of a plant or animal by any suitable method. Such methods may involve, for example, the use of liposomes, electroporation, diffusion, particle bombardment, microinjection, gene gun, chemicals that increase free DNA uptake, e.g., calcium phosphate coprecipitation, viral vectors, and other techniques practiced in the art.

Suitable plant transformation vectors include those derived from a Ti plasmid of *Agrobacterium tumefaciens*, such as those disclosed by Herrera-Estrella (1983), Bevan (1983), Klee (1985) and EPO publication 120,516 (Schilperoort et al.). In addition to plant transformation vectors derived from the Ti or root-inducing (Ri) plasmids of *Agrobacterium*, alternative methods can be used to insert the DNA constructs of this invention into plant cells.

A DNA construct prepared in accordance with the present invention is preferably introduced, via a suitable vector as described above, into cells or protoplasts derived from agriculturally important crops, e.g., dicotyledonous plants such as tobacco, tomato, cotton, watermelon, cucumber, strawberry, rose, sweet pepper, hot pepper, eggplant, apple, citrus, pear, fig, currant, squash, musk melon, sweet potato, blackberry, blueberry, raspberry,

loganberry, other berries, chrysanthemum, among others, or monocotyledonous plants such as the grasses or lilies.

The choice of vector in which the expression cassette of the present invention is operatively linked depends directly, as is well known in the art, on the functional properties desired, e.g., replication, protein expression, and the host cell to be transformed, these being limitations inherent in the art of constructing recombinant DNA molecules. In preferred embodiments, the vector utilized includes a prokaryotic replicon, i.e., a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extra-chromosomally when introduced into a prokaryotic host cell, such as a bacterial host cell. Such replicons are well known in the art. In addition, preferred embodiments that include a prokaryotic replicon also include a gene whose expression confers a selective advantage, such as a drug resistance, to the bacterial host cell when introduced into those transformed cells. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline, among other selective agents. The neomycin phosphotransferase gene has the advantage that it is expressed in eukaryotic as well as prokaryotic cells.

Those vectors that include a prokaryotic replicon also typically include convenient restriction sites for insertion of a recombinant DNA molecule of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322, and pBR329 available from BioRad Laboratories (Richmond, CA) and pPL, pK and K223 available from Pharmacia (Piscataway, NJ), and pBLUESCRIPT and pBS available from Stratagene (La Jolla, CA). A vector of the present invention may also be a Lambda phage vector including those Lambda vectors described in Molecular Cloning: A Laboratory Manual, Second Edition, Maniatis et al., eds., Cold Spring Harbor, NY (1989) and the Lambda ZAP vectors available from Stratagene (La Jolla, CA). Other exemplary vectors include pCMU [Nilsson et al. (1989) *Cell* 58:707]. Other appropriate vectors may also be synthesized, according to known methods; for example, vectors pCMU/K<sup>b</sup> and pCMUII used in various applications herein are modifications of pCMUIV (Nilson et al., supra).

Typical expression vectors capable of expressing a recombinant nucleic acid sequence in plant cells and capable of directing stable integration within the host plant cell include vectors derived from the tumor-inducing (Ti) plasmid of *Agrobacterium tumefaciens*

described by Rogers et al. (1987) *Meth. in Enzymol.* 153:253-277, and several other expression vector systems known to function in plants. See for example, Verma et al., Published PCT Application No. WO87/00551; Cocking and Davey *Science* (1987) 236:1259-1262.

5 In preferred embodiments, the plant cell expression vectors used include a selection marker that is effective in a eukaryotic cell, preferably a drug resistance selection marker. In preferred embodiments where a recombinant nucleic acid molecule of the present invention is expressed in plant cells, a preferred drug resistance marker is the gene whose expression results in kanamycin resistance, i.e., the chimeric gene containing nopaline synthetase  
10 promoter, Tn5 neomycin phosphotransferase II and nopaline synthetase 3' non-translated region described by Rogers et al., *Methods for Plant Molecular Biology*, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San Diego, CA (1988).

A transgenic plant can be produced by any means known to the art, including but not limited to *Agrobacterium tumefaciens*-mediated DNA transfer, preferably with a disarmed T-  
15 DNA vector, electroporation, direct DNA transfer, and particle bombardment (See Davey et al. (1989) *Plant Mol. Biol.* 13:275; Walden and Schell (1990) *Eur. J. Biochem.* 192:563; Joersbo and Burnstedt (1991) *Physiol. Plant.* 81:256; Potrykus (1991) *Annu. Rev. Plant Physiol. Plant Mol. Biol.* 42:205; Gasser and Fraley (1989) *Science* 244:1293; Leemans (1993) *Bio/Technology.* 11:522; Beck et al. (1993) *Bio/Technology.* 11:1524; Koziel et al.  
20 (1993) *Bio/Technology.* 11:194; and Vasil et al. (1993) *Bio/Technology.* 11:1533.).

Techniques are well-known to the art for the introduction of DNA into monocots as well as dicots, as are the techniques for culturing such plant tissues and regenerating those tissues. Monocots which have been successfully transformed and regenerated include wheat, corn, rye, rice and asparagus. For example, U.S. Patent No. 5,350,689 (1994, Shillito et al.)  
25 describes transgenic *Zea mays* plants regenerated from protoplasts and protoplast-derived cells. For efficient production of transgenic plants, it is desired that the plant tissue used for transformation possess a high capacity for regeneration. Transgenic aspen tissue has been prepared and transgenic plants have been regenerated [Devellard et al. (1992) *C.R. Acad. Sci. Ser. VIE* 314:291-298K; Nilsson et al. (1992) *Transgenic Res.* 1:209-220; Tsai et al. (1994)  
30 *Plant Cell Rep.* 14:94-97]. Poplars have also been transformed [Wilde et al. (1992) *Plant Physiol.* 98:114-120]. Technology is also available for the manipulation, transformation and

regeneration of Gymnosperm plants in the laboratory. For example, U.S. Patent No. 5,122,466 (1992, Stomp et al.) describes the ballistic transformation of conifers, with preferred target tissue being meristematic and cotyledon and hypocotyl tissues. U.S. Patent No. 5,041,382 (1991, Gupta et al.) describes enrichment of conifer embryonal cells.

5           Techniques and agents for introducing and selecting for the presence of heterologous DNA in plant cells and/or tissue are well-known. Genetic markers allowing for the selection of heterologous DNA in plant cells are well-known, e.g., genes carrying resistance to an antibiotic such as kanamycin, hygromycin, gentamicin, or bleomycin. The marker allows for selection of successfully transformed plant cells growing in the medium containing the  
10           appropriate antibiotic because they will carry the corresponding resistance gene.

          Other techniques for genetically engineering plant cells and/or tissue with an expression cassette comprising an inducible promoter or chimeric promoter fused to a heterologous coding sequence and a transcription termination sequence are to be introduced into the plant cell or tissue by *Agrobacterium*-mediated transformation, electroporation,  
15           microinjection, particle bombardment or other techniques known to the art. The expression cassette advantageously further contains a marker allowing selection of the heterologous DNA in the plant cell, e.g., a gene carrying resistance to an antibiotic such as kanamycin, hygromycin, gentamicin, or bleomycin.

          The transcription regulatory sequences, particularly the tissue-specific transcription  
20           regulatory element (or the GH3, AGL5 or other ovary and/or developing fruit specific promoter with the inducible and preferably the transcription-enhancing element) is useful in controlling gene expression in transgenic plant cells in suspension cell culture as an alternative to expression in transgenic plants. It is understood that transgenic plants can be similarly used to express heterologous coding sequences as can transgenic plant cells.

25           Many of the procedures useful for practicing the present invention, whether or not described herein in detail, are well known to those skilled in the art of plant molecular biology. Standard techniques for cloning, DNA isolation, amplification and purification, for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like, and various separation techniques are those known and commonly employed by  
30           those skilled in the art. A number of standard techniques are described in Sambrook et al. (1989) *Molecular Cloning*, Second Edition, Cold Spring Harbor Laboratory, Plainview, New

York; Maniatis et al. (1982) *Molecular Cloning*, Cold Spring Harbor Laboratory, Plainview, New York; Wu (ed.) (1993) *Meth. Enzymol.* 218, Part I; Wu (ed.) (1979) *Meth Enzymol.* 68; Wu et al. (eds.) (1983) *Meth. Enzymol.* 100 and 101; Grossman and Moldave (eds.) *Meth. Enzymol.* 65; Miller (ed.) (1972) *Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Old and Primrose (1981) *Principles of Gene Manipulation*, University of California Press, Berkeley; Schleif and Wensink (1982) *Practical Methods in Molecular Biology*; Glover (ed.) (1985) *DA Cloning* Vol. I and II, IRL Press, Oxford, UK; Hames and Higgins (eds.) (1985) *Nucleic Acid Hybridization*, IRL Press, Oxford, UK; and Setlow and Hollaender (1979) *Genetic Engineering: Principles and Methods*, Vols. 1-4, Plenum Press, New York, Kaufman (1987) in *Genetic Engineering Principles and Methods*, J.K. Setlow, ed., Plenum Press, NY, pp. 155-198; Fitch et al. (1993) *Annu. Rev. Microbiol.* 47:739-764; Tolstoshev et al. (1993) in *Genomic Research in Molecular Medicine and Virology*, Academic Press. Abbreviations and nomenclature, where employed, are deemed standard in the field and commonly used in professional journals such as those cited herein.

All references cited in the present application are incorporated by reference herein.

The following examples are provided for illustrative purposes, and are not intended to limit the scope of the invention as claimed herein. Any variations in the exemplified sequences and methods which occur to the skilled artisan are intended to fall within the scope of the present invention.

As used herein, the term "comprising" is intended in a nonlimiting sense.

## EXAMPLES

### Example 1. Production of GH3-iaaM and GH3-ipt Expression Cassettes

The GH3 promoter was cloned from soybean (*Glycine max*) as described by Hagen et al. (1991) *Plant Molec. Biol.* 17:567-579. The nucleotide sequence of the soybean GH3 promoter is given in SEQ ID NO:1. The GH3 promoter was cloned into pUC18 using EcoRI and NcoI.

The *iaaM* and *ipt* genes were cloned using polymerase chain reaction technology from *Agrobacterium tumefaciens* (pTich5). The coding sequences and deduced amino acid

sequences are provided in SEQ ID NO:2-3 and 4-5, respectively. The product of the *iaaM* gene, tryptophan oxygenase, converts tryptophan to indoleacetic acid. The *ipt* gene encodes isopentenyl transferase, an enzyme in the cytokinin biosynthetic pathway.

To make the expression cassettes of the present invention, the coding sequence of the *iaaM* or *ipt* gene was fused with the GH3 promoter sequences cloned in pUC18 at the NcoI and SacI sites. The 3' untranslated NOS gene sequence was purchased from Stratagene, La Jolla, CA, and inserted. The "GH3 promoter-*iaaM*-3'-NOS" and "GH3 promoter-*ipt*-3'-NOS" genes were then cut from the pUC19 using EcoRI and ligated into the EcoRI site of pBIN19 binary vector in separate experiments [Bevan, (1984) *Nucleic Acid Research* 12:8711-8721]. The pBIN19 containing the GH3-*ipt* or GH3-*iaaM* genes were mobilized into *Agrobacterium tumefaciens* strain LBA 4404 using *E. coli* harboring pRK2103 as a helper plasmid [Bevan (1984) *supra*; Ditta et al. (1980) *Proc. Natl. Acad. Sci.* 77:7347-7351]. See Figs. 3 and 4 restriction maps of the GH3-*iaaM*-NOS sequences cloned in pUC18 and pBIN19, respectively. See Figs. 5 and 6 for the GH3-*ipt*-NOS sequences cloned in pUC18 and pBIN19, respectively.

The AGL5 transcription regulatory sequences were similarly cloned and subcloned (See Figs 5-8).

#### Example 2. Production of Transgenic Tomato Plants

Tomato seeds were sterilized using 10% chlorox (5.3% sodium hypochlorite and germinated on MS medium solidified with 0.65% agar at 25°C, 16 hr. photoperiod with light intensity of 35 mEm<sup>2</sup>S<sup>-1</sup> for 5-7 days. Cotyledons of tomato seedlings were removed from young seedlings and wounded by cutting their ends off. The cotyledons were carefully placed on tobacco feeder layer plates upside down under light for 24 hours. *Agrobacterium tumefaciens* strain LBA4404 [Bevan (1984) *supra*] containing the GH3-*iaaM* or GH3-*ipt* expression cassettes were cultured for 2 to 3 days, then diluted and subcultured overnight. The cotyledons were removed from the feeder plates and incubated with the *A. tumefaciens* cultures for 20-30 minutes with occasional swirling. The inoculated cotyledons were then separately transferred to sterile paper filters to remove excess liquid, and placed on tobacco feeder plates upside down. After 48 hours of cocultivation at 25°C, the cotyledons were transferred onto a shoot regeneration medium containing kanamycin and zeatin. Shoots were

formed from the infected edges of the cotyledons after 3-4 weeks. When the shoots were ready for rooting, they were separated from callus tissues and placed on rooting medium containing auxin (IBA). After each shoots reached a height of about 2 inches and had developed a nice root system, it was transferred to soil and placed in a greenhouse to produce seeds.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION

(ii) TITLE OF INVENTION: Transgenic Seedless Plants

5 (iii) NUMBER OF SEQUENCES: 7

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Greenlee, Winner and Sullivan, P.C.

(B) STREET: 5370 Manhattan Circle, Suite 201

10 (C) CITY: Boulder

(D) STATE: Colorado

(E) COUNTRY: US

(F) ZIP: 80303

## (v) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

20 (A) APPLICATION NUMBER: US

(B) FILING DATE: 06-MAY-1998

(C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/045,725

25 (B) FILING DATE: 06-MAY-1997

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ferber, Donna M.

(B) REGISTRATION NUMBER: 33,878

(C) REFERENCE/DOCKET NUMBER: 4-97 WO

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (303) 499-8080

(B) TELEFAX: (303) 499-8089

5 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 749 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic).

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15 GAATTCACGA ATAAAGAAAA ATTAAAAGTC TCAACAAATG TAGTAAGAGG GCAAAAATAG 60  
GCTGTAATAA CTGCAAAGT GTGCAGTGAA GTTTTCTTCG TACTACGTAG AAAC TTCTCA 120  
GTTCTTTCTC ACATTTCTGC CCACAGGGAT TTGGATTTCG TGTATTGACG CAGTTATACC 180  
ATCATTAAATC TTATCCTTCA ATTTTATAA AATTAATAAA ATAAATAAAA AATTAATTAA 240  
GCTTCCGATC TTGACTGCCT GCTTGAATGC GTCGGCGGCG CCCATTAGTT TCTCATGCCA 300  
20 ACACACCCTA TAACGCCTAA TTTTGCCCGA GTATTACTAT ATTGGGAGAA CTTTGTCTGA 360  
CGTGGCGACA CATCTGGACC CACATGTCGG CCACCATGCA CCATCCCTGG CCCTCGTGTC 420

21

TCCTCAATAA GCTACACAAT TTGAAACATA CACGCAATCC TTTGTCTCAA TAAGTTCCAC 480

TCAGGTACTG TTTTCTCCCG CAACCATGAC GTAATTCTGT AAATCACATG TTTCATGCTC 540

CCAATTATTT TCCGCTTCTA TAAATACCTC TCCCATTTCG CAACTTTTCT CCATCCATAC 600

TCATCCACTT CTTGAACCGT GCCTTAACTA AACTAGAGCT AGAATTAGAG TTAGCTACCT 660

5 TGCCTAATTC ACAAACGCGT CCCTCTACGG CTCTACCTAT TAGCTATCTT TTTTGTGCTG 720

TGATTGAAAT TAATTTGTGA TAGCTCACC 749

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 2211 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

15

(iv) ANTI-SENSE: NO

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 4..2205

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

20 ACA ATG GTC GAT AAG GCG GAT GAA TTG GAC CGC AGG GTT TCC GAT GCC 48

Met Val Asp Lys Ala Asp Glu Leu Asp Arg Arg Val Ser Asp Ala

1 5 10 15

22

	TTC TTA GAA CGA GAA GCT TCT AGG GGA AGG AGG ATT ACT CAA ATC TCC	96
	Phe Leu Glu Arg Glu Ala Ser Arg Gly Arg Arg Ile Thr Gln Ile Ser	
	20 25 30	
5	ACC GAG TGC AGC GCT GGG TTA GCT TGC AAA AGG CTG GCC GAT GGT CGC	144
	Thr Glu Cys Ser Ala Gly Leu Ala Cys Lys Arg Leu Ala Asp Gly Arg	
	35 40 45	
	TTC CCC GAG ATC TCA GCT GGT GGA AAG GTA GCA GTT CTC TCC GCT TAT	192
	Phe Pro Glu Ile Ser Ala Gly Gly Lys Val Ala Val Leu Ser Ala Tyr	
	50 55 60	
10	ATC TAT ATT GGC AAA GAA ATT CTG GGG CGG ATA CTT GAA TCG AAA CCT	240
	Ile Tyr Ile Gly Lys Glu Ile Leu Gly Arg Ile Leu Glu Ser Lys Pro	
	65 70 75	
15	TGG GCG CGG GCA ACA GTG AGT GGT CTC GTT GCC ATC GAC TTG GCA CCA	288
	Trp Ala Arg Ala Thr Val Ser Gly Leu Val Ala Ile Asp Leu Ala Pro	
	80 85 90 95	
	TTT TGC ATG GAT TTC TCC GAA GCA CAA CTA ATC CAA GCC CTG TTT TTG	336
	Phe Cys Met Asp Phe Ser Glu Ala Gln Leu Ile Gln Ala Leu Phe Leu	
	100 105 110	
20	CTG AGC GGT AAA AGA TGT GCA CCG ATT GAT CTT AGT CAT TTC GTG GCC	384
	Leu Ser Gly Lys Arg Cys Ala Pro Ile Asp Leu Ser His Phe Val Ala	
	115 120 125	
	ATT TCA ATC TCT AAG ACT GCC GGC TTT CGA ACC CTG CCA ATG CCG CTG	432
	Ile Ser Ile Ser Lys Thr Ala Gly Phe Arg Thr Leu Pro Met Pro Leu	
	130 135 140	
25	TAC GAG AAT GGC ACG ATG AAA TGC GTT ACC GGG TTT ACC ATA ACC CTT	480
	Tyr Glu Asn Gly Thr Met Lys Cys Val Thr Gly Phe Thr Ile Thr Leu	
	145 150 155	

23

	GAA GGG GCC GTG CCA TTT GAC ATG GTA GCT TAT GGT CGA AAC CTG ATG	528
	Glu Gly Ala Val Pro Phe Asp Met Val Ala Tyr Gly Arg Asn Leu Met	
	160 165 170 175	
5	CTG AAG GGT TCG GCA GGT TCC TTT CCA ACA ATC GAC TTG CTC TAC GAC	576
	Leu Lys Gly Ser Ala Gly Ser Phe Pro Thr Ile Asp Leu Leu Tyr Asp	
	180 185 190	
	TAC AGA CCG TTT TTT GAC CAA TGT TCC GAT AGT GGA CGG ATC GGC TTC	624
	Tyr Arg Pro Phe Phe Asp Gln Cys Ser Asp Ser Gly Arg Ile Gly Phe	
	195 200 205	
10	TTT CCG GAG GAT GTT CCT AAG CCG AAA GTG GCG GTC ATT GGC GCT GGC	672
	Phe Pro Glu Asp Val Pro Lys Pro Lys Val Ala Val Ile Gly Ala Gly	
	210 215 220	
	ATT TCC GGA CTC GTG GTG GCA AAC GAA CTG CTT CAT GCT GGG GTA GAC	720
	Ile Ser Gly Leu Val Val Ala Asn Glu Leu Leu His Ala Gly Val Asp	
15	225 230 235	
	GAT GTT ACA ATA TAT GAA GCA AGT GAT CGT GTT GGA GGC AAG CTT TGG	768
	Asp Val Thr Ile Tyr Glu Ala Ser Asp Arg Val Gly Gly Lys Leu Trp	
	240 245 250 255	
	TCA CAT GCT TTC AGG GAC GCT CCT AGT GTC GTG GCC GAA ATG GGG GCG	816
20	Ser His Ala Phe Arg Asp Ala Pro Ser Val Val Ala Glu Met Gly Ala	
	260 265 270	
	ATG CGA TTT CCT CCT GCT GCA TTC TGC TTG TTT TTC TTC CTC GAG CGT	864
	Met Arg Phe Pro Pro Ala Ala Phe Cys Leu Phe Phe Phe Leu Glu Arg	
	275 280 285	
25	TAC GGC CTG TCT TCG ATG AGG CCG TTC CCA AAT CCC GGC ACA GTC GAC	912
	Tyr Gly Leu Ser Ser Met Arg Pro Phe Pro Asn Pro Gly Thr Val Asp	
	290 295 300	

24

	ACT TAC TTG GTC TAC CAA GGC GTC CAA TAC ATG TGG AAA GCC GGG CAG	960
	Thr Tyr Leu Val Tyr Gln Gly Val Gln Tyr Met Trp Lys Ala Gly Gln	
	305 310 315	
5	CTG CCA CCG AAG CTG TTC CAT CGC GTT TAC AAC GGT TGG CGT GCG TTC	1008
	Leu Pro Pro Lys Leu Phe His Arg Val Tyr Asn Gly Trp Arg Ala Phe	
	320 325 330 335	
	TTG AAG GAC GGT TTC TAT GAG CGA GAT ATT GTG TTG GCT TCG CCT GTC	1056
	Leu Lys Asp Gly Phe Tyr Glu Arg Asp Ile Val Leu Ala Ser Pro Val	
	340 345 350	
10	GCT ATT ACT CAG GCC TTG AAA TCA GGA GAC ATT AGG TGG GCT CAT GAC	1104
	Ala Ile Thr Gln Ala Leu Lys Ser Gly Asp Ile Arg Trp Ala His Asp	
	355 360 365	
	TCC TGG CAA ATT TGG CTG AAC CGT TTC GGG AGG GAG TCC TTC TCT TCA	1152
	Ser Trp Gln Ile Trp Leu Asn Arg Phe Gly Arg Glu Ser Phe Ser Ser	
15	370 375 380	
	GGG ATA GAG AGG ATC TTT CTG GGC ACA CAT CCT CCT GGT GGT GAA ACA	1200
	Gly Ile Glu Arg Ile Phe Leu Gly Thr His Pro Pro Gly Gly Glu Thr	
	385 390 395	
	TGG AGT TTT CCT CAT GAT TGG GAC CTA TTC AAG CTA ATG GGA ATA GGA	1248
20	Trp Ser Phe Pro His Asp Trp Asp Leu Phe Lys Leu Met Gly Ile Gly	
	400 405 410 415	
	TCT GGC GGG TTT GGT CCA GTT TTT GAA AGC GGG TTT ATT GAG ATC CTC	1296
	Ser Gly Gly Phe Gly Pro Val Phe Glu Ser Gly Phe Ile Glu Ile Leu	
	420 425 430	
25	CGC TTG GTC ATC AAC GGA TAT GAA GAA AAT CAG CGG ATG TGC CCT GAA	1344
	Arg Leu Val Ile Asn Gly Tyr Glu Glu Asn Gln Arg Met Cys Pro Glu	
	435 440 445	

25

	GGA ATC TCA GAA CTT CCA CGT CGG ATC GCA TCT GAA GTG GTT AAC GGT	1392
	Gly Ile Ser Glu Leu Pro Arg Arg Ile Ala Ser Glu Val Val Asn Gly	
	450 455 460	
5	GTG TCT GTG AGC CAG CGC ATA TGC CAT GTT CAA GTC AGG GCG ATT CAG	1440
	Val Ser Val Ser Gln Arg Ile Cys His Val Gln Val Arg Ala Ile Gln	
	465 470 475	
	AAG GAA AAG ACA AAA ATA AAG ATA AGG CTT AAG AGC GGG ATA TCT GAA	1488
	Lys Glu Lys Thr Lys Ile Lys Ile Arg Leu Lys Ser Gly Ile Ser Glu	
	480 485 490 495	
10	CTT TAT GAT AAG GTG GTG GTC ACA TCT GGA CTC GCA AAT ATC CAA CTC	1536
	Leu Tyr Asp Lys Val Val Val Thr Ser Gly Leu Ala Asn Ile Gln Leu	
	500 505 510	
15	AGG CAT TGC CTG ACA TGC GAT ACC AAT ATT TTT CAG GCA CCA GTG AAC	1584
	Arg His Cys Leu Thr Cys Asp Thr Asn Ile Phe Gln Ala Pro Val Asn	
	515 520 525	
	CAA GCG GTT GAT AAC AGC CAT ATG ACA GGA TCG TCA AAA CTC TTC CTG	1632
	Gln Ala Val Asp Asn Ser His Met Thr Gly Ser Ser Lys Leu Phe Leu	
	530 535 540	
20	ATG ACT GAA CGA AAA TTC TGG TTA GAC CAT ATC CTC CCG TCT TGT GTC	1680
	Met Thr Glu Arg Lys Phe Trp Leu Asp His Ile Leu Pro Ser Cys Val	
	545 550 555	
	CTC ATG GAC GGG ATC GCA AAA GCA GTG TAT TGC CTG GAC TAT GAG CCG	1728
	Leu Met Asp Gly Ile Ala Lys Ala Val Tyr Cys Leu Asp Tyr Glu Pro	
	560 565 570 575	
25	CAG GAT CCG AAT GGT AAA GGT CTA GTG CTC ATC AGT TAT ACA TGG GAG	1776
	Gln Asp Pro Asn Gly Lys Gly Leu Val Leu Ile Ser Tyr Thr Trp Glu	
	580 585 590	

26

	GAC GAC TCC CAC AAG CTG TTG GCG GTC CCC GAC AAA AAA GAG CGA TTA	1824
	Asp Asp Ser His Lys Leu Leu Ala Val Pro Asp Lys Lys Glu Arg Leu	
	595 600 605	
5	TGT CTG CTG CGG GAC GCA ATT TCG AGA TCT TTC CCG GCG TTT GCC CAG	1872
	Cys Leu Leu Arg Asp Ala Ile Ser Arg Ser Phe Pro Ala Phe Ala Gln	
	610 615 620	
	CAC CTA TTT CCT GCC TGC GCT GAT TAC GAC CAA AAT GTT ATT CAA CAT	1920
	His Leu Phe Pro Ala Cys Ala Asp Tyr Asp Gln Asn Val Ile Gln His	
	625 630 635	
10	GAT TGG CTT ACA GAC GAG AAT GCC GGG GGA GCT TTC AAA CTC AAC CGG	1968
	Asp Trp Leu Thr Asp Glu Asn Ala Gly Gly Ala Phe Lys Leu Asn Arg	
	640 645 650 655	
15	CGT GGT GAG GAT TTT TAT TCT GAA GAA CTT TTC TTT CAA GCA CTG GAC	2016
	Arg Gly Glu Asp Phe Tyr Ser Glu Glu Leu Phe Phe Gln Ala Leu Asp	
	660 665 670	
	ACG GCT AAT GAT ACC GGA GTT TAC TTG GCG GGT TGC AGT TGT TCC TTC	2064
	Thr Ala Asn Asp Thr Gly Val Tyr Leu Ala Gly Cys Ser Cys Ser Phe	
	675 680 685	
20	ACA GGT GGA TGG GTG GAG GGT GCT ATT CAG ACC GCG TGT AAC GCC GTC	2112
	Thr Gly Gly Trp Val Glu Gly Ala Ile Gln Thr Ala Cys Asn Ala Val	
	690 695 700	
	TGT GCA ATT ATC CAC AAT TGT GGA GGC ATT TTG GCA AAG GGC AAT CCT	2160
	Cys Ala Ile Ile His Asn Cys Gly Gly Ile Leu Ala Lys Gly Asn Pro	
	705 710 715	
25	CTC GAA CAC TCT TGG AAG AGA TAT AAC TAC CGC ACT AGA AAT TAG	2205
	Leu Glu His Ser Trp Lys Arg Tyr Asn Tyr Arg Thr Arg Asn *	
	720 725 730	
	GAGCTC	2211

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 734 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Val Asp Lys Ala Asp Glu Leu Asp Arg Arg Val Ser Asp Ala Phe  
1 5 10 15

10 Leu Glu Arg Glu Ala Ser Arg Gly Arg Arg Ile Thr Gln Ile Ser Thr  
20 25 30

Glu Cys Ser Ala Gly Leu Ala Cys Lys Arg Leu Ala Asp Gly Arg Phe  
35 40 45

15 Pro Glu Ile Ser Ala Gly Gly Lys Val Ala Val Leu Ser Ala Tyr Ile  
50 55 60

Tyr Ile Gly Lys Glu Ile Leu Gly Arg Ile Leu Glu Ser Lys Pro Trp  
65 70 75 80

Ala Arg Ala Thr Val Ser Gly Leu Val Ala Ile Asp Leu Ala Pro Phe  
85 90 95

20 Cys Met Asp Phe Ser Glu Ala Gln Leu Ile Gln Ala Leu Phe Leu Leu  
100 105 110

Ser Gly Lys Arg Cys Ala Pro Ile Asp Leu Ser His Phe Val Ala Ile  
115 120 125

28

Ser Ile Ser Lys Thr Ala Gly Phe Arg Thr Leu Pro Met Pro Leu Tyr  
 130 135 140

Glu Asn Gly Thr Met Lys Cys Val Thr Gly Phe Thr Ile Thr Leu Glu  
 145 150 155 160

5 Gly Ala Val Pro Phe Asp Met Val Ala Tyr Gly Arg Asn Leu Met Leu  
 165 170 175

Lys Gly Ser Ala Gly Ser Phe Pro Thr Ile Asp Leu Leu Tyr Asp Tyr  
 180 185 190

10 Arg Pro Phe Phe Asp Gln Cys Ser Asp Ser Gly Arg Ile Gly Phe Phe  
 195 200 205

Pro Glu Asp Val Pro Lys Pro Lys Val Ala Val Ile Gly Ala Gly Ile  
 210 215 220

Ser Gly Leu Val Val Ala Asn Glu Leu Leu His Ala Gly Val Asp Asp  
 225 230 235 240

15 Val Thr Ile Tyr Glu Ala Ser Asp Arg Val Gly Gly Lys Leu Trp Ser  
 245 250 255

His Ala Phe Arg Asp Ala Pro Ser Val Val Ala Glu Met Gly Ala Met  
 260 265 270

20 Arg Phe Pro Pro Ala Ala Phe Cys Leu Phe Phe Phe Leu Glu Arg Tyr  
 275 280 285

Gly Leu Ser Ser Met Arg Pro Phe Pro Asn Pro Gly Thr Val Asp Thr  
 290 295 300

Tyr Leu Val Tyr Gln Gly Val Gln Tyr Met Trp Lys Ala Gly Gln Leu  
 305 310 315 320

29

Pro Pro Lys Leu Phe His Arg Val Tyr Asn Gly Trp Arg Ala Phe Leu  
 325 330 335

Lys Asp Gly Phe Tyr Glu Arg Asp Ile Val Leu Ala Ser Pro Val Ala  
 340 345 350

5 Ile Thr Gln Ala Leu Lys Ser Gly Asp Ile Arg Trp Ala His Asp Ser  
 355 360 365

Trp Gln Ile Trp Leu Asn Arg Phe Gly Arg Glu Ser Phe Ser Ser Gly  
 370 375 380

10 Ile Glu Arg Ile Phe Leu Gly Thr His Pro Pro Gly Gly Glu Thr Trp  
 385 390 395 400

Ser Phe Pro His Asp Trp Asp Leu Phe Lys Leu Met Gly Ile Gly Ser  
 405 410 415

Gly Gly Phe Gly Pro Val Phe Glu Ser Gly Phe Ile Glu Ile Leu Arg  
 420 425 430

15 Leu Val Ile Asn Gly Tyr Glu Glu Asn Gln Arg Met Cys Pro Glu Gly  
 435 440 445

Ile Ser Glu Leu Pro Arg Arg Ile Ala Ser Glu Val Val Asn Gly Val  
 450 455 460

20 Ser Val Ser Gln Arg Ile Cys His Val Gln Val Arg Ala Ile Gln Lys  
 465 470 475 480

Glu Lys Thr Lys Ile Lys Ile Arg Leu Lys Ser Gly Ile Ser Glu Leu  
 485 490 495

Tyr Asp Lys Val Val Val Thr Ser Gly Leu Ala Asn Ile Gln Leu Arg  
 500 505 510

30

His Cys Leu Thr Cys Asp Thr Asn Ile Phe Gln Ala Pro Val Asn Gln  
 515 520 525

Ala Val Asp Asn Ser His Met Thr Gly Ser Ser Lys Leu Phe Leu Met  
 530 535 540

5 Thr Glu Arg Lys Phe Trp Leu Asp His Ile Leu Pro Ser Cys Val Leu  
 545 550 555 560

Met Asp Gly Ile Ala Lys Ala Val Tyr Cys Leu Asp Tyr Glu Pro Gln  
 565 570 575

10 Asp Pro Asn Gly Lys Gly Leu Val Leu Ile Ser Tyr Thr Trp Glu Asp  
 580 585 590

Asp Ser His Lys Leu Leu Ala Val Pro Asp Lys Lys Glu Arg Leu Cys  
 595 600 605

Leu Leu Arg Asp Ala Ile Ser Arg Ser Phe Pro Ala Phe Ala Gln His  
 610 615 620

15 Leu Phe Pro Ala Cys Ala Asp Tyr Asp Gln Asn Val Ile Gln His Asp  
 625 630 635 640

Trp Leu Thr Asp Glu Asn Ala Gly Gly Ala Phe Lys Leu Asn Arg Arg  
 645 650 655

20 Gly Glu Asp Phe Tyr Ser Glu Glu Leu Phe Phe Gln Ala Leu Asp Thr  
 660 665 670

Ala Asn Asp Thr Gly Val Tyr Leu Ala Gly Cys Ser Cys Ser Phe Thr  
 675 680 685

Gly Gly Trp Val Glu Gly Ala Ile Gln Thr Ala Cys Asn Ala Val Cys  
 690 695 700

31

Ala Ile Ile His Asn Cys Gly Gly Ile Leu Ala Lys Gly Asn Pro Leu  
 705 710 715 720

Glu His Ser Trp Lys Arg Tyr Asn Tyr Arg Thr Arg Asn \*  
 725 730

5 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 745 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 3..725

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CC ATG GAC CTG CAT CTA ATT TTC GGT CCA ACT TGC ACA GGA AAG ACG 47  
 Met Asp Leu His Leu Ile Phe Gly Pro Thr Cys Thr Gly Lys Thr  
 20 1 5 10 15

ACG ACC GCG ATA GCT CTT GCC CAG CAG ACA GGG CTT CCA GTC CTT TCG 95  
 Thr Thr Ala Ile Ala Leu Ala Gln Gln Thr Gly Leu Pro Val Leu Ser  
 20 25 30

CTT GAT CGG GTC CAA TGC TGT CCT CAA CTA TCA ACC GGA AGC GGA CGA 143  
 Leu Asp Arg Val Gln Cys Cys Pro Gln Leu Ser Thr Gly Ser Gly Arg  
 35 40 45

33

TTG CAG CTT GAC GCA AAT ATG GAA GGT AAG TTG ATT AAT GGG ATC GCT 623  
Leu Gln Leu Asp Ala Asn Met Glu Gly Lys Leu Ile Asn Gly Ile Ala  
195 200 205

5 CAG GAG TAT TTC ATC CAT GCG CGC CAA CAG GAA CAG AAA TTC CCC CAA 671  
Gln Glu Tyr Phe Ile His Ala Arg Gln Gln Glu Gln Lys Phe Pro Gln  
210 215 220

GTT AAC GCA GCC GCT TTC GAC GGA TTC GAA GGT CAT CCG TTC GGA ATG 719  
Val Asn Ala Ala Ala Phe Asp Gly Phe Glu Gly His Pro Phe Gly Met  
225 230 235

10 TAT TAG GTTACGCCAG CCCTGAGCTC 745  
Tyr \*  
240

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 241 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

20 Met Asp Leu His Leu Ile Phe Gly Pro Thr Cys Thr Gly Lys Thr Thr  
1 5 10 15  
Thr Ala Ile Ala Leu Ala Gln Gln Thr Gly Leu Pro Val Leu Ser Leu  
20 25 30  
Asp Arg Val Gln Cys Cys Pro Gln Leu Ser Thr Gly Ser Gly Arg Pro  
25 35 40 45

34

Thr Val Glu Glu Leu Lys Gly Thr Thr Arg Leu Tyr Leu Asp Asp Arg  
 50 55 60

Pro Leu Val Glu Gly Ile Ile Ala Ala Lys Gln Ala His His Arg Leu  
 65 70 75 80

5 Ile Glu Glu Val Tyr Asn His Glu Ala Asn Gly Gly Leu Ile Leu Glu  
 85 90 95

Gly Gly Ser Thr Ser Leu Leu Asn Cys Met Ala Arg Asn Ser Tyr Trp  
 100 105 110

10 Ser Ala Asp Phe Arg Trp His Ile Ile Arg His Lys Leu Pro Asp Gln  
 115 120 125

Glu Thr Phe Met Lys Ala Ala Lys Ala Arg Val Lys Gln Met Leu His  
 130 135 140

Pro Ala Ala Gly His Ser Ile Ile Gln Glu Leu Val Tyr Leu Trp Asn  
 145 150 155 160

15 Glu Pro Arg Leu Arg Pro Ile Leu Lys Glu Ile Asp Gly Tyr Arg Tyr  
 165 170 175

Ala Met Leu Phe Ala Ser Gln Asn Gln Ile Thr Ala Asp Met Leu Leu  
 180 185 190

20 Gln Leu Asp Ala Asn Met Glu Gly Lys Leu Ile Asn Gly Ile Ala Gln  
 195 200 205

Glu Tyr Phe Ile His Ala Arg Gln Gln Glu Gln Lys Phe Pro Gln Val  
 210 215 220

Asn Ala Ala Ala Phe Asp Gly Phe Glu Gly His Pro Phe Gly Met Tyr  
 225 230 235 240

25 \*

36

(C) STRANDEDNESS: double  
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

	GAAAATGATG AGGAATGGGC AAAACACAAA AGAGTTTCCT TTCGTAATA CAATTAATTA	60
	ATGCAAATCT GAGAAAGGGT TCATGGATAA TGAATACACA CATGATTAGT CATTCCCCGT	120
	GGGCTCTCTG CTTTCATTTA CTTTATTAGT TTCATCTTCT CTAATTATAT TGTCGCATAT	180
	GATGCAGTTC TTTTGTCTAA ATTACGTAAT ATGATGTAAT TAATTATCAA AATAATATTA	240
10	ACGACATGCA ATGTATATAG GAGTAGGGCA ATAAAAAGAA AAGGAGAATA AAAAGGGATT	300
	ACCAAAAAAG GAAAGTTTCC AAAAGGTGAT TCTGATGAGA AACAGAGCCC ATACCTCTCT	360
	TTTTTCCTCT AAACATGAAA GAAAAATTGG ATGGTCCTCC TTCAATGCTC TCTCCCCACC	420
	CAATCCAAAC CCAACTGTCT TCTTTCTTTC TTTTCTTCTC TTTCTATTG ATATTTTCTA	480
	CCACTTAATT CCAATCAATT TCAAATTTCA ATCTAAATGT ATGCATATAG GAATTTAATT	540
15	AAAAGAATTA GGTGTGTGAT ATTTGAGAAA ATGTTAGAAG TAATGGTCCA TGTCTTTCT	600
	TTCTTTTTC TTCTATAACA CTTCAAGTTG AAAAAAACT ACCAAACCTT CTGTTTCTG	660
	CAAATGGGTT TTAAATACT TCCAAAGAAA TATTCCTCTA AAAGAAATTA TAAACCAAAA	720
	CAGAAACCAA AAACAAAAA TAAAGTTGAA GCAGCAGTTA AGTGGTACTG AGATAATAAG	780
	AATAGTATCT TTAGGCCAAT GAACAAATTA ACTCTCTCAT AATTCATCTT CCCATCCTCA	840

37

CTTCTCTTTC TTTCTGATAT AATTAATCTT GCTAAGCCAG GTATGGTTAT TGATGATTTA	900
CACTTTTTTT TAAAAGTTTC TTCCTTTTCT CCAATCAAAT TCTTCAGTTA ATCCTTATAA	960
ACCATTTCTT TAATCCAAGG TGTTTGAGTG CAAAAGGATT TGATCTATTT CTCTTGTGTT	1020
TATACTTCAG CTAGGGCTTA TATAGAAAAT G	1051

## WHAT IS CLAIMED IS:

1. A DNA construct comprising a first portion encoding an isopentenyl transferase or a tryptophan oxygenase enzyme and a second portion which is a plant-expressible promoter which is specifically expressed in the ovary or developing fruit of a plant,  
5 said promoter portion being operably linked to the first portion.
2. The DNA construct of claim 1 wherein the plant-expressible promoter is a GH3 promoter having a nucleotide sequence as given in SEQ ID NO:1.
3. The DNA construct of claim 1 wherein the plant-expressible promoter is an AGL promoter having a nucleotide sequence as given in SEQ ID NO:7.
- 10 4. The DNA construct of claim 1 wherein said plant-expressible promoter is a PLE36 promoter.
5. The DNA construct of any of claims 1 through 4 wherein the encoded isopentenyl transferase has an amino acid sequence as given in SEQ ID NO:5.
6. The DNA construct of any of claims 1 through 4 where in the encoded tryptophan  
15 oxygenase having an amino acid sequence as given in SEQ ID NO:3.
7. A transgenic plant comprising the DNA construct of any of claims 1 through 6.
8. The transgenic plant of claim 7, wherein said plant is a dicotyledonous plant.
9. The transgenic plant of claim 7, wherein said dicotyledonous plant is a tomato,  
20 cucumber, watermelon, tobacco, apple, citrus, pear, fig, currant, muskmelon, squash,  
cherry, sweet potato, grape, sugar beet, tea, strawberry, blackberry, blueberry,  
raspberry, loganberry, rose, chrysanthemum, sweet pepper or eggplant.
10. The transgenic plant of claim 7 which is a tomato plant.
11. The transgenic plant of claim 7 which is a watermelon plant.
12. The transgenic plant of claim 7 which is a cucumber plant.
- 25 13. A method for producing a transgenic plant which produces substantially seedless fruit increased in solids content, said method comprising the steps of:  
(a) introducing into a plant cell or plant tissue the DNA construct of any of claims 1 through 6 to produce a transformed plant cell or a transformed plant tissue; and  
(b) regenerating the transformed plant cell or transformed plant tissue of step (a) to  
30 produce a transgenic plant,

whereby the transgenic plant produces substantially seedless fruit when grown under conditions which allow flowering and fruit development.

14. The method of claim 13 wherein said plant is a dicotyledonous plant.
15. The method of claim 14 wherein said dicotyledonous plant is a tomato, cucumber,  
5 watermelon, tobacco, apple, citrus, pear, fig, currant, muskmelon, squash, cherry, sweet potato, grape, sugar beet, tea, strawberry, blackberry, blueberry, raspberry, loganberry, rose, chrysanthemum, sweet pepper or an eggplant plant.
16. The method of claim 14, wherein said plant is a tomato plant.
17. The method of claim 14, wherein said plant is a watermelon plant.
- 10 18. The method of claim 14, wherein said plant is a cucumber plant.
19. A transgenic seed or a transgenic embryo comprising the construct of any of claims 1 through 6.
20. The transgenic seed or transgenic embryo of claim 18, wherein said seed or embryo is of a dicotyledonous plant.
- 15 21. The transgenic seed or transgenic embryo of claim 19, wherein said seed or embryo is a tomato, cucumber, watermelon, tobacco, apple, citrus, pear, fig, currant, muskmelon, squash, cherry, sweet potato, grape, sugar beet, tea, strawberry, blackberry, blueberry, raspberry, loganberry, rose, chrysanthemum, sweet pepper or eggplant seed or embryo.
- 20 22. The transgenic seed or transgenic embryo of claim 20 which is a tomato seed or embryo.
23. The transgenic seed or transgenic embryo of claim 20 which is a watermelon seed or embryo.
24. The transgenic seed or embryo of claim 20 which is a cucumber seed or embryo.

1/4

wildtype  
seeded

GH3-iaaM  
seedless

GH3-ipt  
seedless




FIG. 1



wildtype  
seedless



GH3-iaaM  
seedless


GH3-ipt  
seedless




FIG. 2

**FIG. 3****FIG. 4**

**FIG. 5****FIG. 6**




**FIG. 7**



**FIG. 8**

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US98/09013

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : A01H 5/00, 5/10; C12N 5/14, 15/31, 15/52, 15/82 US CL : 435/172.3, 320.1, 419; 536/23.2, 23.7; 800/205, 250 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/172.3, 320.1, 419; 536/23.2, 23.7; 800/205, 250 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P — Y,P	ROTINO et al. Genetic Engineering of Parthenocarpic Plants. Nature Biotechnology. December 1997, Vol. 15, pages 1398-1401, see entire article.	1, 6 ----- 2-5
X — Y	MARTINEAU et al. Production of High Solids Tomatoes Through Molecular Modification of Levels of the Plant Growth Regulator Cytokinin. Bio/Technology. March 1995, Vol. 13, pages 250-254, see entire article.	1, 5 ----- 2-4, 6
Y	LI et al. Transgenic Tobacco Plants that Overproduce Cytokinins Show Increased Tolerance to Exogenous Auxin and Auxin Transport Inhibitors. Plant Science. 1994. Vol. 100, pages 9-14, see Abstract, page 10.	1-5
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family		
Date of the actual completion of the international search 02 JULY 1998		Date of mailing of the international search report 1 8 AUG 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  AMY NELSON Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/09013

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,175,095 A (MARTINEAU et al) 29 December 1992, see entire article.	1, 4-6
Y	SAVIDGE et al. Temporal Relationship between the Transcription of Two Arabidopsis MADS Box Genes and the Floral Organ Identity Genes. The Plant Cell. June 1995, Vol. 7, pages 721-733, see Abstract, page 727.	1, 3, 5-6
Y	HAGEN et al. Auxin-induced Expression of the Soybean GH3 Promoter in Transgenic Tobacco Plants. Plant Molecular Biology 1991, Vol. 17, pages 567-579, see Abstract, Figure 1, pages 572-576.	1-2, 5-6

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/09013

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☒ Claims Nos.: 7-24  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/09013

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN, BIOSIS, EMBASE, AGRICOLA, CA, WPIDS

search terms: isopentenyl transferase, tryptophan oxidase, ipt, iaaM, GH3, AGL, PLE36, fruit, seed, ovary, seedless, parthenocarpic